Versant Trims LENZ Stake, Realizes $10M+ in June Insider Sales
Rhea-AI Filing Summary
Form 4 highlights for LENZ Therapeutics, Inc. (LENZ) filed 20-Jun-2025:
Multiple Versant Venture–affiliated funds, each classified as a 10% beneficial owner, reported open-market sales of LENZ common stock on 18-Jun-2025 and 20-Jun-2025.
- 18-Jun-2025: Versant Venture Capital VII, L.P. (indirect holding) sold 100,000 shares at $29.95.
- 20-Jun-2025: The same fund sold an additional 100,877 shares at $30.35.
- 20-Jun-2025: Versant Venture Capital VI, L.P. (direct holding) sold 133,924 shares at $30.25.
Total shares disposed across the two trading days amount to 334,801 shares, representing gross proceeds of roughly $10.1 million based on the stated sale prices.
Post-sale ownership:
- Versant Venture Capital VII, L.P. now holds 1,047,912 shares (indirect).
- Versant Venture Capital VI, L.P. now holds 1,967,275 shares (direct).
- Versant Vantage II, L.P. continues to hold 842,162 shares (indirect, no new transactions).
All reporting entities remain above the 10 % threshold and continue to be classified as insiders. No derivative transactions were reported. The filing does not disclose reasons for the sales or any 10b5-1 trading plan reliance, therefore investors should interpret the activity strictly as open-market disposals by a significant shareholder.
Positive
- None.
Negative
- Large insider selling: Versant entities disposed of 334,801 shares, representing roughly 14 % of their prior holdings, which can signal reduced confidence or create share overhang.
Insights
TL;DR: 10% owner Versant sold 335k LENZ shares (~$10m) but still retains large stake; signals modest negative sentiment.
Three sizeable open-market sales by Versant funds reduce their collective position by roughly 14 % (334,801 shares vs. 2.86 million pre-sale). While Versant remains a strategic holder, trimming at ~$30 suggests profit-taking near recent highs. No offsetting insider purchases or option exercises were disclosed, and no 10b5-1 checkbox was marked, implying discretionary selling. Absent fundamental news, such sales are often interpreted as a mildly bearish indicator, especially given Versant’s board representation potential. However, the group still owns more than 3.8 million shares, limiting immediate governance impact. Investors should monitor further filings for a trend.
TL;DR: Insider sales by a control-level holder raise governance and overhang considerations for LENZ.
Versant’s status as a >10 % holder gives it significant influence; any reduction in stake can alter control dynamics. Though the funds remain insiders, cumulative disposition of ~335 k shares introduces additional free float and potential share-price pressure. The absence of a stated Rule 10b5-1 plan leaves open the question of timing rationale. Nevertheless, Versant’s layered GP/LP structure, as detailed in the footnotes, continues to exercise voting power over nearly 3.9 million shares, so board dynamics are unlikely to shift immediately. From a governance standpoint, disclosure is complete and timely; impact is modest but directionally negative if further sales follow.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 100,877 | $30.35 | $3.06M |
| Sale | Common Stock | 133,924 | $30.25 | $4.05M |
| Sale | Common Stock | 100,000 | $29.95 | $3.00M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
